CoChat

FXN methylation predicts expression and clinical outcome in Friedreich ataxia

Open access
Evans‐Galea, Marguerite V., Carrodus, Nissa, Rowley, Simone M., Corben, Louise A., Tai, Geneieve, Saffery, Richard, Galati, John C., Wong, Nicholas C., Craig, Jeffrey M., Lynch, David R., Regner, Sean R., Brocht, Alicia F. D., Perlman, Susan L., Bushara, Khalaf O., Gomez, Christopher M., Wilmot, George R., Li, Lingli, Varley, Elizabeth, Delatycki, Martin B., Sarsero, Joseph P. · 2012 · Annals of Neurology
Cited by 119

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Objective: Friedreich ataxia (FA) is the most common ataxia and results from an expanded GAA repeat in the first intron of FXN. This leads to epigenetic modifications and reduced frataxin. We investigated the relationships between genetic, epigenetic, and clinical parameters in a large case–control study of FA. Methods: Clinical data and samples were obtained from individuals with FA during annual visits to our dedicated FA clinic. GAA expansions were evaluated by polymerase chain reaction (PCR) and restriction endonuclease digest. DNA methylation was measured using bisulfite‐based EpiTYPER MassARRAY (Sequenom, San Diego, CA). FXN expression was determined using real‐time reverse transcriptase PCR. Significant correlations between the different parameters were examined using the nonparametric Spearman rank correlation coefficient, as well as univariate and multivariate regression modeling. Results: Characteristic DNA methylation was identified upstream and downstream of the expansion, and validated in an independent FA cohort. Univariate and multivariate analyses showed significant inverse correlations between upstream methylation and FXN expression, and variation in downstream methylation and age of onset. FXN expression also inversely correlated with the Friedreich Ataxia Rating Scale score, an indicator of disease severity. Interpretation: These novel findings provide compelling evidence for the link between the GAA expansion, the DNA methylation profile, FXN expression, and clinical outcome in FA. Epigenetic profiling of FXN could be used to gain greater insight into disease onset and progression, but also as a biomarker to learn more about specific treatment responses and pharmacological mechanism(s). This work also highlights the potential for developing therapies aimed at increasing frataxin levels to treat this debilitating disease. ANN NEUROL 2012;

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.22671

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 119

Metadata

Authors
Evans‐Galea, M. V., Carrodus, N., Rowley, S. M., Corben, L. A., Tai, G., Saffery, R., Galati, J. C., Wong, N. C., Craig, J. M., Lynch, D. R., Regner, S. R., Brocht, A. F. D., Perlman, S. L., Bushara, K. O., Gomez, C. M., Wilmot, G. R., Li, L., Varley, E., Delatycki, M. B., & Sarsero, J. P.
Venue
Annals of Neurology
Publisher
Wiley
Published
2012-04
Volume
71
Issue
4
Pages
487-497
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W1986826633
Cited by
119
References
6
FWCI
4.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FXN methylation predicts expression and clinical outcome in Friedreich ataxia. https://app.cochat.ai/papers/10.1002/ana.22671
The paper
Evans‐Galea, M. V., Carrodus, N., Rowley, S. M., Corben, L. A., Tai, G., Saffery, R., Galati, J. C., Wong, N. C., Craig, J. M., Lynch, D. R., Regner, S. R., Brocht, A. F. D., Perlman, S. L., Bushara, K. O., Gomez, C. M., Wilmot, G. R., Li, L., Varley, E., Delatycki, M. B., & Sarsero, J. P. (2012). FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Annals of Neurology. https://doi.org/10.1002/ana.22671

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.